- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12.25 | RedChip Companies, Inc.: Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 455 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip... ► Artikel lesen | |
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Calidi BioTherapeutics GAAP EPS of -$2.21 misses by $0.53 | 1 | Seeking Alpha | ||
| 13.11.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights | 443 | GlobeNewswire (Europe) | Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform... ► Artikel lesen | |
| 13.11.25 | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | Cha Biotech's Matica Bio, Calidi partner on cancer immunotherapy project | 2 | Korea Herald | ||
| 24.10.25 | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.09.25 | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.08.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights | 320 | GlobeNewswire (Europe) | Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune... ► Artikel lesen | |
| 01.08.25 | RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 601 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip... ► Artikel lesen | |
| 25.07.25 | Calidi Biotherapeutics, Inc: Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 | 345 | GlobeNewswire (Europe) | SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted... ► Artikel lesen | |
| 27.06.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEO | 295 | GlobeNewswire (Europe) | SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted... ► Artikel lesen | |
| 14.05.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights | 231 | GlobeNewswire (Europe) | Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered... ► Artikel lesen | |
| 25.04.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 195 | GlobeNewswire (Europe) | SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
| 31.03.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights | 128 | GlobeNewswire (Europe) | Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial... ► Artikel lesen | |
| 14.03.25 | RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 392 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip... ► Artikel lesen | |
| 10.03.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform | 329 | GlobeNewswire (Europe) | SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,30 | +0,27 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| MODERNA | 45,140 | -0,15 % | Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash | ||
| OCUGEN | 1,644 | -0,75 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,845 | +1,16 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| ABCELLERA BIOLOGICS | 3,284 | +0,37 % | What Sparked AbCellera Biologics To Soar Over 9% After Hours | ||
| ADAPTIMMUNE THERAPEUTICS | 0,011 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 4,840 | -1,22 % | Sagimet Biosciences Inc.: Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| QIAGEN | 41,295 | -1,58 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,790 Euro und damit -3,08 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.